Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2004-08-27
2010-11-23
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S234100, C424S239100, C424S247100, C514S002600
Reexamination Certificate
active
07838008
ABSTRACT:
Methods for treating diverse cancers by local administration of a botulinum toxin to or to the vicinity of the cancer.
REFERENCES:
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5466672 (1995-11-01), Kushnaryov
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6261572 (2001-07-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6565870 (2003-05-01), Donovan
patent: 6667041 (2003-12-01), Schmidt
patent: 2001/0043930 (2001-11-01), Aoki et al.
patent: 2002/0094339 (2002-07-01), Brin et al.
patent: 2003/0224019 (2003-12-01), O'Brien
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2004/0180065 (2004-09-01), Schmidt
patent: 2005/0031648 (2005-02-01), Brin et al.
patent: 19802569 (1998-01-01), None
patent: 198 52 981 (1998-11-01), None
patent: 2142032 (1985-01-01), None
patent: 2142032 (1985-01-01), None
patent: WO 94/24155 (1994-10-01), None
patent: 95 17904 (1995-07-01), None
patent: WO95/17904 (1995-07-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 00/10598 (2000-03-01), None
patent: WO 00/15245 (2000-03-01), None
patent: WO 00/33880 (2000-06-01), None
patent: WO01/41790 (2000-08-01), None
patent: WO 00/57897 (2000-10-01), None
patent: WO 00/74703 (2000-12-01), None
patent: 01 21213 (2001-03-01), None
patent: WO01/41790 (2001-08-01), None
patent: WO 02/07759 (2002-01-01), None
patent: WO 02/09743 (2002-02-01), None
patent: WO02/74327 (2002-03-01), None
patent: WO 02/074327 (2002-09-01), None
patent: WO 02/074327 (2002-09-01), None
patent: WO 03/011333 (2003-02-01), None
patent: WO2004/071525 (2003-02-01), None
Johnson and Goldin. The clinical impact of screening and other experimental tumor studies. Cancer Treat. Reviews 2: 1-31, 1975.
Johnson (Neurotoxigenic Clostridia. In: Fischetti, V.A. (EDS) Gram-Positive Pathogens. ASM Press, Washington, DC. pp. (540-550).
Hatheway (Clinical Microbiology Reviews 3(1): 66-98, Jan. 1990).
Wald and Kakulas (The Australian and New Zealand Journal of Surgery 33(3): 200-204, Feb. 1964).
Bejjani, J. Neurosurg 92(4), pp. 615-625, Apr. 2000.
Blasi, Nature 365, pp. 160-163, Sep. 9, 1993.
Boyd,Mov Disord, 10(3):376:1995.
Dayanithi, Neuroscience 39(3), pp. 711-715, 1990.
Doggweiler, Neurourol Urodyn 17(4), p. 363, 1998.
Habermann,Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14thedition, published by McGraw Hill.
Hohne-Zell, Endocrinology 138, pp. 5518-5526, 1997.
Lawrence, Eur. J. Biochem. 236, pp. 877-886, 1996.
Nowinski, IEEE Trans Med Imaging 19(1), pp. 62-69, 2000.
Sadoul, J. Cell. Biology 128, pp. 1019-1029, Mar. 1995.
Weigand et al,Naunyn-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165.
Lin, J.C., et al.;Cardiac Pheochromocytoma: Resection After Diagnosis by 111-Indium Octreotide Scan; Ann Thorac Surg(1999); 67:555-558.
Naumann, M., et al.;Botulinum Toxin in the Treatment of Neurological Disorders of the Autonomic Nervous System; Arch Neurol(Aug. 1999); 56:914-916.
Ragona, R.M., et al.;Management of Parotid Sialocele with Botulinum Toxin; Laryngoscope;(Aug. 1999); 109: 1344-1346.
Sanchez-Prieto, J., et al.;Botulinum Toxin A Blocks. Glutamate Exocytosis from Guinea-Pig Cerebral Cortical Synaptosomes; Eur. J. Biochem.(1987); 165:675-681.
Schweitzer, E.S., et al.;Inhibition of Regulated Catecholamine Secretion from PC12 Cells by the Ca2+/Calmodulin Kinase II Inhibitor KN-62; Journal of Cell Science; (1995); 108:2619-2628.
Sigma;Biochemicals and Reagents for Life Science Research; p. 187-188, 1999.
Walther, M.M., et al.;Pheochromocytoma: Evaluation, Diagnosis, and Treatment; World J Urol(1999); 17:35-39.
Warwar, R.E., et al.;Coexistence of 3 Tumors of Neural Crest Origin; Arch Ophthalmol(Sep. 1998); 116:1241-1243.
Williamson, L.C., et al.;Clostridial Neurotoxins and Substrate Proteolysis in Intact Neurons; The Journal of Biological Chemistry(Mar. 29, 1996); vol. 271, No. 13; pp. 7694-7699.
Bagshawe, K.D., et al.;Antibody Directed Enzyme Prodrug Therapy(Adept):Clinical Report; Disease Markers; vol. 9:233-238 (1991).
Bagshawe, K.D., et al.;A Cytotoxic Agent can be Generated Selectively at Cancer Sites; Br. J. Cancer; 58:700-703 (1988).
Bryan, M.;Glomus Tumors; Dept. of Otolaryngology, UTMB;—10 pages (Jan. 11, 1995).
Eccles, S.A., et al.;Regression of Established Breast Carcinoma Xenografts with Antibody-Directed Enzyme Prodrug Therapy Against c-erbB2 p185; Cancer Research; 54:5171-5177 (Oct. 1, 1994).
Heppner, F.;New Technologies to Combat Malignant Tumours of the Brain; Anticancer Research; 2:101-110 (1982).
Jankovic, J., et al., editors;Therapy with Botulinum Toxin; Marcel Dekker, Inc. publisher; p. 45 (1994).
Lemmon, J.J., et al.;Anaerobic Bacteria as a Gene Delivery System to Tumors; Proceedings of the American Association for Cancer Research; vol. 35:374 (Mar. 1994).
Manger, W.M., et al.;Clinical and Experimental Pheochromocytoma; Second Edition; Blackwell Science, Inc. publisher (1996).
Robinson, R.;Tumours that Secrete Catecholamines—Their Detection and Clinical Chemistry; John Wiley & Sons, Ltd. publisher (1980).
Springer, C.J., et al;Ablation of Human Choriocarcinoma Xenografts in Nude Mice by Antibody-Directed Enzyme Prodrug Therapy(ADEPT)with Three Novel Compounds; Eur J Cancer; 27(11):1361-1366 (1991).
Xu, T., et al.;Kinetic Studies of Ca2+ Binding and Ca2+ Clearance in the Cytosol of Adrenal Chromaffin Cells; Biophysical Journal; vol. 73:532-535 (Jul. 1997).
Bigalke, H., et al.;Botulinum a Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture; Brain Research, 360 (1985); 318-324.
Bigalke, H., et al.;Tetanus Toxin and Botulinum A. Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord; Naunyn-Schmiedeberg's Arch. Pharmacol(1981); 316:244-251.
Col, V., et al.;Heart Failure Induced by Pheochromocytoma: Laparoscopic Treatment and Intraoperative Changes of Several New Cardiovascular Hormones; Hormone Research(1999); 51:50-52.
Habermann, E., et al.;Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain; Journal of Neurochemistry; vol. 51; No. 2 (1988); 522-527.
John, H., et al.;Pheochromocytomas: Can Malignant Potential be Predicted?; Urology(1999); 53(4):679-683.
Laskawi, R., et al.;Up-to-Date Report of Botulinum Toxin Type A Treatment in Patients with Gustatory Sweating(Frey's Syndrome);Laryngoscope; (Mar. 1998); 108:381-384.
Meyer, K.E.,A Comparative Systemic Toxicity Study of Neurobloc in Adult and Juvenile Cynomolgus Monkeys, Mov Disord2000;15(Suppl 2):54.
B. Anabel et al: “Dual effects of botulinum neurotoxin A on the secretory stages of chromaffin cells.” Euro J. Neuro 10:3369-3378; 1998.
F. Patrick et al: “Blockade by botulinum neurotoxin B of catechalamine release from adrenchromaffin cells correlates with its cleavage of synaptobrevin and a homologue present on the granules.” Biochem, vol. 34, No. 16, 1995, pp. 5494-5503.
One Man's Poison—Clinical Applications of Botulinum Toxin, The New England Journal of Medicine, Jul. 18, 1999, pp. 118-120, Mark Hallett.
Botulinum Toxin: Potent Poison, Potent Medicine, Hosp Pract Apr. 15, 1999;34(4):87-91, L.L. Simpson.
Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine, Microbiological Reviews, Mar. 1992, pp. 80-99, E.J. S
Brin Mitchell F.
Donovan Stephen
Allergan Inc.
Condino Debra
Donovan Stephen
Harris Alana M
Nassif Claude
LandOfFree
Methods for treating diverse cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating diverse cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating diverse cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209912